Published peptide research references
Ganirelix acetate
Governed registry record
4 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.
Approved source records
Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation.
DOI: 10.1016/s0015-0282(00)01638-1
Source identity and connection checked by Codex (AI).
Efficacy and safety of newly developed ganirelix acetate in infertile women for assisted reproductive technology: a prospective, randomised, controlled study.
DOI: 10.1080/01443615.2022.2036955
Source identity and connection checked by Codex (AI).
Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome.
Source identity and connection checked by Codex (AI).
Ganirelix acetate.
Source identity and connection checked by Codex (AI).
Legacy research context
Context from the legacy curated dataset. Its counts describe that dataset and are separate from the live approved source records above.
Researchers represented
- Han EJ
- Lyu SW
- Kwak IP
- Kwon H
- Choi DH
- Kim JY
- Park HM
- Kim JW
- Chang EM
- Lee HJ
- Kim MK
- Lee HN
- Park S
- Lee WS
- Fluker M
- Grifo J
- Leader A
- Levy M
- Meldrum D
- Muasher SJ
- Rinehart J
- Rosenwaks Z
- Scott RT Jr
- Schoolcraft W
- Shapiro DB
- North American Ganirelix Study Group
- Gustofson RL
- Segars JH
- Larsen FW